December 2, 1985European Heart Journal
Risk/Benefit Analysis of Intracoronary Thrombolytic Therapy in Evolving Myocardial Infarction
Why the study?
Does intracoronary streptokinase administration reduce mortality and improve left ventricular function in patients with acute myocardial infarction?
Population
258 patients with acute myocardial infarction
Comparison
Acute cardiac catheterisation and intracoronary… vs Prospective control group
Design
Cohort
Authors
Discussion
Loading...
Member takes
Implication
May support streptokinase consideration in younger AMI patients; leaves open need for randomized confirmation before practice change.
Structured PICO
Does intracoronary streptokinase administration reduce mortality and improve left ventricular function in patients with acute myocardial infarction?
P
Population
258 patients with acute myocardial infarction
I
Intervention
Acute cardiac catheterisation and intracoronary streptokinase administration
C
Comparator
Prospective control group (patients who refused the protocol or met exclusion criteria)
O
Outcome
Mortality and left ventricular functionhard clinical
Intracoronary streptokinase therapy during evolving myocardial infarction significantly reduces mortality in patients under 65 years of age, particularly those with anterior myocardial infarction.
Cite This Study
Smalling et al. (1985) studied this question.